32 completed, 12 unknown, 6 not yet recruiting, 6 recruiting. 16 Not applicable, 10 Phase 2, 10 Phase 3, 8 Phase 1, 4 Phase 4.
Follow HCV: new trials by email Literature Review of HCV trials Research Report on HCV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Facilitated Telemedicine in the Bassett Health System HCV | Not yet recruiting | State University of New York at Buffalo | 200 | 2026-12-01 | 2026-10-08 | |
| HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking Sex Trafficking Survivor-Developed Digital Crowdsourced Intervention - HIV Testing, STI | Not applicable | Not yet recruiting | Columbia University | 368 | 2026-10-01 | 2026-01-28 |
| National Rapid TLC: Testing and Linkage to Care Xpert® HIV-1 Qual XC - HIV, Chlamydia | Not applicable | Not yet recruiting | Unity Health Toronto | 2500 | 2026-08-01 | 2026-07-28 |
| HIV/HBV/HCV Triple Screening in Primary Care electronic medical record alert linked to orders - HIV, HBV (Hepatitis B Virus) | Not applicable | Not yet recruiting | University of Texas Southwestern Medical Center | 50 | 2026-06-01 | 2026-04-29 |
| Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland HIV (Human Immunodeficiency Virus), Chlamydia | Not yet recruiting | University of Zurich | 1800 | 2026-04-07 | 2026-04-08 | |
| Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide HBV, HBV Coinfection | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 20 | 2025-09-24 | 2026-02-24 | |
| Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis) Multiplex Testing of HIV, HBV, HCV and Syphilis, HIV | Recruiting | MagIA Diagnostics | 2950 | 2025-07-29 | 2026-02-02 | |
| Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada Preimplementation of HCV Point of care testing - HCV, HEPATITIS C VIRUS CHRONIC INFECTION | Recruiting | McGill University | 300 | 2025-05-20 | 2025-07-31 | |
| Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria HBV, HCV | Recruiting | Vanessa Stadlbauer-Koellner, MD | 100 | 2025-05-01 | 2026-06-18 | |
| Innovate, Involve, Inspire Community-based Simplified HCV Testing and Treatment Algorithm - HCV | Not applicable | Unknown | Frontline AIDS | 1454 | 2025-01-01 | 2024-09-19 |
| Current Situation of Health Care in Women With HBV or HCV Infection HBV, HCV | Unknown | Ruijin Hospital | 2500 | 2024-09-01 | 2024-08-30 | |
| The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City Ganchero intervention - HIV Infections, HCV | Not applicable | Active not recruiting | North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI) | 69 | 2024-05-01 | 2026-07-24 |
| Xpert Hepatitis-C Virus (HCV) Test on the GeneXpert Xpress System Xpert HCV - HCV | Completed | Cepheid | 1012 | 2024-02-06 | 2024-07-19 | |
| Community Intervention to Eliminate HCV Among People Who Use Drugs. Hybrid effectiveness-implementation study type 2 - HCV, Substance Use Disorders | Not applicable | Active not recruiting | ANRS, Emerging Infectious Diseases | 3400 | 2023-10-02 | 2025-09-08 |
| National Prisons Hepatitis Education Project: Research Evaluation Education Intervention (The HepPEd Program) - HCV | Not applicable | Unknown | Kirby Institute | 3000 | 2023-09-04 | 2024-03-06 |
| Tools to Identify People At Risk or Already Infected with HIV and HCV rapid HIV and HCV serological tests - HIV/AIDS, STD | Not applicable | Unknown | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 240000 | 2023-07-01 | 2025-03-03 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients Prophylaxis (P2W), Transmit and Treat (T&T) - HCV | Not applicable | Recruiting | Johns Hopkins University | 120 | 2023-04-19 | 2026-09-04 |
| Simplified HCV Integrated Management Model in Methadone Clinics in Ukraine Simplified HCV Integrated Management, Pay-for-performance, Case Management and Referral - HCV, Opioid Use Disorder | Not applicable | Completed | Ukrainian Institute on Public Health Policy | 616 | 2023-03-04 | 2026-09-16 |
| Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC) Biomarker dosage - HCC, Cirrhosis, Liver | Unknown | Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis | 60 | 2023-02-24 | 2024-04-08 |
Showing 20 of 64. Sign in to see all of them.
Hepatitis C (26) · Acquired Immunodeficiency Syndrome (6) · HIV Infections (6) · Hepatitis C, Chronic (6) · Hepatitis B (4) · Sexually Transmitted Diseases (4) · Drug Overdose (3) · Fibrosis (3) · Liver Cirrhosis (3) · Non-alcoholic Fatty Liver Disease (3) · Carcinoma, Hepatocellular (2) · Chlamydia Infections (2) · Communicable Diseases (2) · Gonorrhea (2) · Syphilis (2)
Infections (39) · Communicable Diseases (36) · Virus Diseases (35) · Blood-Borne Infections (34) · RNA Virus Infections (34) · Digestive System Diseases (31) · Liver Diseases (30) · Hepatitis (28) · Hepatitis, Viral, Human (27) · Flaviviridae Infections (26) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Genital Diseases (15) · Urogenital Diseases (15) · Disease Attributes (13)
Ribavirin (7) · glecaprevir (6) · pibrentasvir (6) · glecaprevir and pibrentasvir (5) · Ritonavir (4) · Sofosbuvir (4) · Simeprevir (3) · ABT-072 (2) · Tablets (2) · Telemedicine (2) · daclatasvir (2) · danoprevir (2) · paritaprevir (2) · ravidasvir (2) · sofosbuvir-velpatasvir drug combination (2)
AbbVie (5) · Assiut University (3) · Tibotec Pharmaceuticals, Ireland (3) · AbbVie (prior sponsor, Abbott) (2) · Ain Shams University (2) · Ascletis Pharmaceuticals Co., Ltd. (2) · Columbia University (2) · Icahn School of Medicine at Mount Sinai (2) · ANRS, Emerging Infectious Diseases (1) · Assistance Publique - Hôpitaux de Paris (1) · Atea Pharmaceuticals, Inc. (1) · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis (1) · Beckman Coulter, Inc. (1) · Benha University (1) · Cepheid (1)
United States (22) · Canada (5) · France (4) · Italy (4) · China (3) · Egypt (3) · India (3) · Spain (3) · Pakistan (2) · Philippines (2) · Puerto Rico (2) · South Korea (2) · Argentina (1) · Australia (1) · Austria (1)
Ahlam Farghaly, Professor (1) · Alissa Davis, PhD (1) · Andrea D. Branch, PhD (1) · Andrew H Talal, MD, MPH (1) · Armen Asatryan, MD (1) · Carl Latkin, PhD (1) · Christine Durand, MD (1) · Daniel Cohen (1) · Daniel Cohen, MD (1) · Daniel Feaster, Ph.D (1) · David R Nelson, MD (1)
PMID 30012435, PMID 30923816, PMID 30977945, PMID 30868245, PMID 31568620, PMID 15585, PMID 19960, PMID 22913681, PMID 23439262, PMID 25451053, PMID 28128852, PMID 28412293, PMID 28521, PMID 30529905, PMID 31401140, PMID 32009165, PMID 32156618, PMID 34023351, PMID 34252301, PMID 41408357, PMID 41823658
2015 (3), 2014 (1), R01DA045713 (1), R01DA050470 (1), R01NR019512 (1), R34DA063049 (1), U01AI157931 (1)